美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · INO近 30 天 5 則 · 第 1 / 1 頁
- Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
- Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms
- Can Papzimeos Drive Precigen's Growth Through the Rest of 2026?
- Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP
- INOVIO to Participate in Upcoming Investor Conferences
- Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...
- Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
- Inovio Pharmaceuticals Q2 Earnings Call Highlights
- INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- INOVIO to Report Second Quarter Financial Results on August 12, 2026
- INOVIO Announces Pricing of $20.0 Million Public Offering
- INOVIO Announces Proposed Public Offering
- INOVIO to Participate in Upcoming Scientific and Investor Conferences
- Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
- INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial
- Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
- Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
- Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in ...
- Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings Call
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。